ClinicalTrials.gg
RecruitingNCT06208267TXAUpdated Apr 28, 2026

Tranexamic Acid Use on Pain, Mobility and Bleeding Following Total Hip and Total Knee Arthroplasty

An interventional study of Tranexamic acid in Postoperative Bleeding, sponsored by St. Mary's Research Center, Canada. Recruiting at 1 site in Canada. Open to participants aged 18 Years and older, including healthy volunteers. Per ClinicalTrials.gov, last updated 2026-04-28.

Sponsored by St. Mary's Research Center, Canada · Not applicable, Interventional, and Treatment

How we know

From the registry’s dates

  • Started Aug 2025; still recruiting 1 year 3 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
210
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-21

Among 25 studies testing Tranexamic Acid in Postoperative Hemorrhage — 5 open to participants now, 5 under way, 1 of them phase 3. Tranexamic Acid · Postoperative Hemorrhage.

Planned enrollment
5th of 25
210 · median 116
Started
2025
with 2 others
No phase
5 of 25
1 open now
Registered
21st of 25
by date

Among the 25 studies testing Tranexamic Acid in Postoperative Hemorrhage, this one is the 5th largest by planned enrollment, is one of 3 that started in 2025, is one of 5 with no phase, and was the 21st registered.

Postoperative Hemorrhage

135 studies on the registry are indexed under Postoperative Hemorrhage; 31 are open to participants now.

Browse Postoperative Hemorrhage studies →

Open to participants now

5 of the 25 studies testing Tranexamic Acid in Postoperative Hemorrhage are open now, in 4 countries. Recruiting first, the newest first:

By country, each count listing its studies:

All 5 open studies →

About Tranexamic Acid

Tranexamic Acid: first FDA approval 1986 (CYKLOKAPRON). What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 17 Postoperative Hemorrhage studies recruiting now, 11 (65%) set no upper age limit and 4 (24%) stop at 75 or younger; 2 take children under 18; 6 take healthy volunteers.

This study: 18 Years and older · all sexes · healthy volunteers too.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 25 studies testing Tranexamic Acid in Postoperative Hemorrhage, or all of them as a file.
02

Study summary

Tranexamic acid (TXA) is an anti-fibrinolytic agent developed in the 1960s that has been safely used to reduce blood loss, transfusion rates and bleeding-associated mortality in trauma, obstetrics and orthopedic surgery, including hip fracture care and arthroplasty.

The efficacy and safety profile of TXA has been extensively studied in numerous clinical trials and observational studies. Its wide range of applications, combined with its favourable risk-benefit ratio, has led to the incorporation of TXA into clinical guidelines and protocols worldwide.

This RCT aims to compare the current standard dosing for TXA to additional TXA doses given orally post-operatively for THA and TKA patients. The goal is to compare the following between study groups: visible bleeding on post-operative dressing, mobilization (steps, amount of time moving around), pain (visual analog scale), function (Oxford hip and knee scales) and ROM at four to six weeks.

Read the detailed description

Total knee arthroplasty (TKA) and total hip arthroplasty (THA) are some of the most common surgical procedures performed in elderly patients, with the main indication being end-stage osteoarthritis. While these procedures can result in a significant amount of bleeding, pain and stiffness post-operatively, they have been increasingly performed as day surgeries and with reduced length of stay.

Tranexamic acid (TXA) is an anti-fibrinolytic agent developed in the 1960s that has been safely used to reduce blood loss, transfusion rates and bleeding-associated mortality in trauma, obstetrics and orthopedic surgery, including hip fracture care and arthroplasty.

The efficacy and safety profile of TXA has been extensively studied in numerous clinical trials and observational studies. Its wide range of applications, combined with its favourable risk-benefit ratio, has led to the incorporation of TXA into clinical guidelines and protocols worldwide.

The current standard of care at St-Mary's for TXA use is one gram given intravenously (IV) at the beginning of the replacement and one gram given during cementation. However, despite the established benefits of TXA, the optimal dosing regimen continues to be an area of ongoing research and discussion.

TXA and post-operative hemoglobin and hematocrit levels The use of TXA in knee and hip arthroplasty has been shown to have clear and significant benefits in reducing the post-operative drop in hemoglobin (Hb) and hematocrit (Hct) but the duration of use has ranged from a single pre-operative dose to a prolonged 14-day course. Researchers reported higher post-operative Hb and Hct following THA and TKA using a three-day course of TXA compared to a single pre-operative dose of 1.5g. However another study, showed no added benefit of the addition of a second post-operative dose to the single pre-operative dose. Similarly, an randomized controlled trial (RCT) comparing TXA doses at pre, during and three hours post-operative to the same with additional doses at six and 12 hours and showed no added benefit of the additional two doses on Hb or Hct levels. In contrast to this, three RCTs performed in 2019 and 2021 showed improved Hb and Hct levels with TXA use beyond a minimum of seven hours post-operatively and two involved the use of TXA given by mouth (PO), which is ideal in the ambulatory setting.

TXA and Ambulation/Motion The majority of the studies involving varying doses of TXA following THA and TKA have not assessed articular motion nor ambulation post-operatively. These can have an impact on patient satisfaction as well as the ability to mobilize and be able to leave the hospital earlier. TXA was compared to placebo and demonstrated that patients who received TXA ambulated 20% more during physiotherapy sessions. Several TXA regimens with patients receiving a minimum of three post-operative doses (maximum of four post-operative doses were studied),showed having significantly better range of motion (ROM) than patients who received less. Additionally, these patients reported less post-operative pain.

TXA and Complications

No increase in adverse events were reported in any of these studies following prolonged TXA use. Cardiovascular events, deep vein thrombosis (DVT), pulmonary embolism (PE), renal failure or superficial thrombosis were not different among study groups in the rare cases where they occurred, even with oral TXA given for up to 14 days post-operatively

. At St-Mary's Hospital, we perform a large number of TKAs and THAs, around 1100 per year (600 knees, 500 hips), making us the most productive hospital performing these procedures in Québec. Also, partly driven by the constraints of the pandemic over the past three years, we have successfully and safely reduced the length of stay for our patients and converted hundreds of patients to day surgery. Bleeding, however, remains a significant source of patient anxiety, with 10% of our ambulatory cases needing additional CLSC care or even return to hospital. Rapid mobilization and decrease in post- operative pain are also key factors for a rapid and safe discharge from hospital.

In this RCT, we aim to compare our current standard dosing for TXA to additional TXA doses given orally post-operatively for our THA and TKA patients. We will be the first of this type of study to assess patient mobility using a wearable device that will allow for precise measurement of step counts, amount of time moving around and sleep times. Also new compared to previous studies, will be our assessment of bleeding complications requiring intervention and needs for additional hospital or nursing visits, both of which have and impact on the cost of care. Pain (VAS scale), function (Oxford hip and knee scales) and ROM will also be assessed at 4-6 weeks.

03

Conditions studied

  • Postoperative Bleeding
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

° All adults undergoing primary TKA and THA at St-Mary's Hospital

Exclusion criteria

Exclusion Criteria:

  • Age \< 18 years
  • Known or allergy to TXA
  • Previous history of thromboembolic disease
  • Active (all current cancers other than local skin cancer)
  • Significant renal disease (hematuria, dialysis, kidney transplant)
  • History of convulsions
  • Known defective colour vision
  • Inability or unwillingness to use MyMobility app
  • Unable to communicate in French or English
Terms in these criteria, in plain language(2)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

05

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Triple (Participant, Care provider, Investigator)
Enrollment
210 participants (estimated)

Study arms

  • Active comparator
    1)Standard care: 1G TXA IV

    1 gm TA IV given prior to incision and 1G TXA IV during cementation or closure

    Drug: Tranexamic acid

  • Active comparator
    2) Standard + 1G oral TXA - 0 and 8 hours post-operatively

    Standard + 1G oral TXA given at 0 and 8 hours post-operatively

    Drug: Tranexamic acid

  • Active comparator
    3) Standard + 1G oral TXA given at 0, 8, 16 and 24 hours post-operatively

    Standard + 1G oral TXA given at 0, 8, 16 and 24 hours post-operatively

    Drug: Tranexamic acid

Interventions

  • This is a 3 arm RCT using the three dosage regimens mentioned above. Placebo doses will be provided for the 0, 8, 16 and 24 hours without TXA

    Also known as: CYKLOKAPRON

06

What researchers measure

Primary outcomes

  1. Step counts at 24 and 48 hours post -operative

    We hypothesize that patients receiving additional doses of TXA will mobilize more at 24 and 48 hours post- operatively and that this will be dose-dependent.

    Time frame: Post-operative

Secondary outcomes

  1. Range of motion (ROM) of the hip (if applicable):

    Measuring ROM of the hip taken pre-operatively, post-operatively and 4 to 6 weeks post-operatively if patient received a total hip arthroplasty (THA)

    Time frame: 4 - 6 weeks post op

  2. Range of motion (ROM) of the knee (if applicable):

    Measuring ROM of the knee taken pre-operatively, post-operatively and 4 to 6 weeks post-operatively if patient received a total knee arthroplasty (TKA).

    Time frame: 4 - 6 weeks post op

  3. Patient self-assessment of functionality and pain measured pre-operatively, 4 to 6 weeks postoperatively, 3 months postoperatively and 6 months post-operatively following total hip arthroplasty utilizing the Oxford Hip Score (OHS):

    Minimal value of 0 and maximal value of 48. The higher scores indicate more satisfactory joint function.

    Time frame: 4 to 6 weeks postoperatively, 3 months postoperatively and 6 months post-operatively

  4. Patient self-assessment of functionality and pain measured pre-operatively, 4 to 6 weeks postoperatively, 3 months postoperatively and 6 months post-operatively following total knee arthroplasty utilizing the Oxford Knee Score (OKS):

    joint function.

    Time frame: 4 to 6 weeks postoperatively, 3 months postoperatively and 6 months post-operatively

  5. Bleeding Complications requiring intervention

    Bleeding that require a specific intervntion from CLSC/Clinic/Hospital visits

    Time frame: Return to the emergency room or bleeding complications will be noted.

  6. Daily step counts

    To be measured with an application (MyMobility) on a smartphone or smartwatch used by the patient. This is a numerical value simply describing the number of steps taken by the patient on a day-to-day basis. This measurement will be collected pre-operatively (until OR), on post-operative day 0,1,2,3,5,7 and 4 to 6 weeks postoperatively.

    Time frame: Post-operative day 0,1,2,3,5,7 and 4 to 6 weeks postoperatively.

  7. Measure of quality of life using the 12-Item Short Form Survey (SF-12):

    Regarding minimum and maximum values, there are two summary scores that are reported from the SF-12: there is a mental component score (MCS-12) and a physical component score (PCS-12). The scores may also be reported as Z-scores where a difference would be compared to the population average. In the literature, SF-12 results have also been computed as a range going from a minimum value of 0 to a maximum value of 100, where higher scores indicate better physical and mental health functioning.

    Time frame: This measurement will be taken pre-operatively, 4 to 6 weeks postoperatively, 3 months postoperatively and 6 months post-operatively.

  8. Assessment and screening for depression and anxiety in patients utilizing the Hospital Anxiety Depression Scale (HADS) :

    Minimum score of 0 and maximum score of 21. The higher scores indicate higher distress.

    Time frame: Pre-operative

  9. Reported pain self-reported in patient journal and possibly in-patient charts:

    This is a numerical value. Patient journals and/or in-patient charts, if applicable, would be screened for frequency of opioid use as a way of evaluating pain management post-operatively.

    Time frame: These journals and/or in-patient charts will be verified on postoperative day 0,1,2,3,5 and 7.

  10. Assessment of catastrophic thinking related to pain utilizing the Pain Catastrophizing Scale (PCS):

    Minimum score of 0 and maximum score of 52. The higher scores indicate higher levels of catastrophizing.

    Time frame: Pre-operative

  11. Reported pain using the visual analog pain (VAS) scale:

    The pain VAS scale involves a numerical rating scale or a descriptive rating scale that progressively goes from a minimal value indicating severe pain to a maximal value indicating good pain management.

    Time frame: This measurement will be collected on postoperative day 0, 1,2,3,5 and 7.

07

Study locations

1 of 1 sites recruiting
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Aug 2025 (actual). Primary completion is estimated for Apr 2027, 20 months after the start.

Of 35 non-industry interventional studies with no phase under Postoperative Hemorrhage, half reached primary completion within 14 months of starting (the median), counting those still running; a quarter within 10 and three quarters within 23. This study's planned 20 months is above that.

Counting every sponsor, half of 38 studies reached it within 14 months; a quarter within 8 and three quarters within 23.

How these figures are worked out, and which studies are left out of them.

Registered
Nov 2, 2023
First posted
Jan 17, 2024
StartActual
Aug 20, 2025
Primary completionEst.
Apr 2027
CompletionEst.
Jul 2027
Last update
Apr 28, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Apr 28, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT06208267
Lead sponsor
St. Mary's Research Center, Canada
Responsible party
Anthony Albers, MD (Director of Orthopaedic Research, Orthopaedic Surgeon, St. Mary's Research Center, Canada) — Principal investigator
First posted
Jan 17, 2024
Start date
Aug 20, 2025
Primary completion
Apr 2027 (estimated)
Completion
Jul 2027 (estimated)
Last update
Apr 28, 2026

Study contacts

Jennifer Mutch, MDCM, FRCSC
Contact
j.mutch.ortho@gmail.com
514 345 3511 ext. 3282
Sandhya Baskaran, MBA, M.ED
Contact
sandhya.baskaran.comtl@ssss.gouv.qc.ca
514 239 0042
Jennifer Mutch, MDCM, FRCSC
principal investigator · St. Mary's Hospital Centre

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Tranexamic Acid

Start the discussion